A Randomized & Observational phase II trial comparing the activity of TrabectedIn vs gemCitabine in patients with metastatic or locally advanced LEiomyosarcoma pretreated with conventional chemotherapy
- Conditions
- Metastatic or locally advanced leiomyosarcomaMedDRA version: 21.1Level: PTClassification code: 10024189Term: Leiomyosarcoma Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10024191Term: Leiomyosarcoma metastatic Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10024192Term: Leiomyosarcoma non-metastatic Class: 10029104Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutics [E02]Therapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2024-513820-40-00
- Lead Sponsor
- Italian Sarcoma Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Patients with histologically documented diagnosis of leiomyosarcoma, All previous anticancer treatments must have completed = 3 weeks (21 days) prior to first dose of study drug., The patient has resolution of adverse events, with the exception of alopecia, and of all clinically significant toxic effects of prior loco-regional therapy, surgery, radiotherapy or systemic anticancer therapy to = Grade 1, by National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0, Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted at screening and repeated within 7 days prior to start of treatment: a. Hemoglobin = 9 g/dl b. Absolute neutrophil count (ANC) =1,500/mm3 c. Platelet count=100000/mm3 d. Total bilirubin = upper limit of normal (ULN) () e. Aspartate aminotransferase (AST) (Serum Glutamic Oxaloacetic Transaminase (SGOT)) / Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT)) = 2.5 x institutional upper limit of normal. f. Alkaline phosphatase = 2.5 x ULN (consider hepatic isoenzymes 5-nucleotidase or gamma glutamyl transpeptidase (GGT) if the elevation could be osseous in origin). g. PT-INR/PTT < 1.5 x ULN (Patients who are being therapeutically anticoagulated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists). h. Serum creatinine = 1.5 x ULN or creatinine clearance estimated of =30 mL/min using the Cockcroft-Gault equation or based on a 24 hour urine test : Estimated creatinine clearance = (140-age [years]) x weight (kg) (x F)a / [serum creatinine (mg/dL) x 72]. a where F=0.85 for females and F=1 for males Albumin > 25 g/l i. Albumin = 25 g/l j. Creatine phosphokinase (CPK) = 2.5 x ULN, Left Ventricular Ejection Fraction = 50% and/or above lower institutional limit of normality, Female patients of child-bearing potential must have negative pregnancy test within 7 days before initiation each cycle of chemotherapy. Post-menopausal women must be amenorhoic for at least 12 months to be considered of non-childbearing. potential. Male and female patients of reproductive potential must agree to employ an effective method of birth control during the trial and thereafter, at the end of study treatment, for 3 months in female patients of childbearing potential and for 6 months in men in fertile age, No history of arterial and/or venous thromboembolic event within the previous 12 months., The patient or legal representative must be able to read and understand the informed consent form and must have been willing to give written informed consent prior to any study specific procedure. The subject may also provide an optional consent for the biological/translational sub-study associated. However, the subject may participate in the main trial without participating in biological/translational., Patients with diagnosis of unresectable or metastatic leiomyosarcoma, Patients who received previous first line systemic treatment with Anthracycline-based chemotherapy for advanced disease., Patients suitable to receive gemcitabine or Trabectedin therapy, Measurable or evaluable disease with RECIST 1.1 criteria., Evidence of progression according RECIST 1.1 during the 6 months before study entry, Availability of the following dates (DD/MM/AAAA): start date of the first line treatment, date of the last radiological assessment showing RECIS
Prior treatment with Trabectedin and/or Gemcitabine, Active clinically serious infections (> grade 2 NCI-CTCAE version 5.0)., Previous treatment with radiation therapy within 14 days of first day of study drug dosing, Major surgery within 4 weeks prior to study entry, Concomitant use of known strong CYP3A inhibitors (eg. Ketoconazole, itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (eg. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil), Concomitant use of known strong (eg. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John’s Wort) or moderate CYP3A inducers (eg. bosentan, efavirenz, modafinil)., Patients undergoing renal dialysis or with ClCr <30 ml/min or Creatinine >1,5 mg/dL, Pregnant or breast feeding patients, Patients with severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol., Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation of the study drugs, History of other malignancies (except basal cell carcinoma or cervical carcinoma in situ, adequately treated), unless in remission from 5 years or more and judged of negligible potential of relapse., Persistent toxicities(=CTCAE grade 2) with the exception of alopecia, caused by previous anticancer therapies, Metastatic brain or meningeal tumors (unless the patient is > 6 months from definitive therapy, does not require corticosteroid treatment, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry), Active viral hepatitis(HBV or HCV infection). Active hepatitis B virus (HBV) is defined by a known positive HBV surface antigen (HBsAg) result. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody and absence of HBsAg) are eligible. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA., Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV)., Patients with any severe and/or uncontrolled medical conditions such as unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction = 6 months, serious uncontrolled cardiac arrhythmia, uncontrolled hyperlipidemia, cirrhosis, chronic or persistent active hepatitis or severely impaired lung function. In particular for history of cardiac disease: congestive heart failure = NYHA class 2; active coronary artery disease (myocardial infarction more than 6 months prior to study entry is allowed); cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted) or uncontrolled hypertension, unstable spinal cord compression (untreated and unstable for at least 28 days prior to study entry),superior vena cava syndrome, extensive bilateral lung disease on High Resolution CT sca, Medical history of hemorrhage or a bleeding event = Grade 3 (NCI-CTCAE v 5.0) within 4 weeks prior to the initiation of study treatment
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method